Liu and colleagues also demonstrated that MSNs encapsulating anti-PD-L1 antibody, and a Ying-yang-1 inhibitor could target multiple pathological aspects of hepatocellular carcinoma (HCC) 29. This evidence concerns the gene CD274 and hepatocellular carcinoma.